Ninerafaxstat is under clinical development by Imbria Pharmaceuticals and currently in Phase II for Coronary Artery Disease (CAD) (Ischemic Heart Disease). According to GlobalData, Phase II drugs for Coronary Artery Disease (CAD) (Ischemic Heart Disease) have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ninerafaxstat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ninerafaxstat is under development for the treatment of non-obstructive hypertrophic cardiomyopathy, myocardial ischemia, myocardial fibrosis, coronary artery disease (CAD), diabetic cardiomyopathy, stable angina and diastolic heart failure (HFpEF). It is administered through oral route as tablet. It was under development for systolic heart failure, refractory angina.
Imbria Pharmaceuticals overview
Imbria Pharmaceuticals is a biotechnology company that designed to translate the understanding of cellular metabolism into innovative medicines. The company is headquartered in United States.
For a complete picture of Ninerafaxstat’s drug-specific PTSR and LoA scores, buy the report here.